{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:42:31Z","timestamp":1778593351488,"version":"3.51.4"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T00:00:00Z","timestamp":1540857600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,1]]},"DOI":"10.1093\/rheumatology\/key312","type":"journal-article","created":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T15:19:11Z","timestamp":1537456751000},"page":"352-360","source":"Crossref","is-referenced-by-count":25,"title":["Exposure\u2013response analyses demonstrate no evidence of interleukin 17A contribution to efficacy of ABT-122 in rheumatoid or psoriatic arthritis"],"prefix":"10.1093","volume":"58","author":[{"given":"Amit","family":"Khatri","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Kl\u00fcnder","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul M","family":"Peloso","sequence":"additional","affiliation":[{"name":"Department of Clinical Development, AbbVie Inc., North Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed A","family":"Othman","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,10,29]]},"reference":[{"key":"key\n\t\t\t\t2019012308090983800_key312-B1","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.semarthrit.2016.05.012","article-title":"Psoriasis, psoriatic arthritis, and rheumatoid arthritis: is all inflammation the same?","volume":"46","author":"Coates","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"key\n\t\t\t\t2019012308090983800_key312-B2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cyto.2017.04.012","article-title":"Immunomodulation of autoimmune arthritis by pro-inflammatory cytokines","volume":"98","author":"Kim","year":"2017","journal-title":"Cytokine"},{"key":"key\n\t\t\t\t2019012308090983800_key312-B3","doi-asserted-by":"crossref","DOI":"10.1007\/s12016-017-8630-7","article-title":"Clinical features of psoriatic arthritis: a comprehensive review of unmet clinical needs","author":"McArdle","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"key\n\t\t\t\t2019012308090983800_key312-B4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13075-017-1265-5","article-title":"Mitigation of disease- and treatment-related risks in patients with psoriatic arthritis","volume":"19","author":"Bergman","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t2019012308090983800_key312-B5","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t2019012308090983800_key312-B6","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019012308090983800_key312-B7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t2019012308090983800_key312-B8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/OARRR.S56073","article-title":"Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders","volume":"9","author":"D'Angelo","year":"2017","journal-title":"Open Access Rheumatol"},{"key":"key\n\t\t\t\t2019012308090983800_key312-B9","doi-asserted-by":"crossref","first-page":"ii30","DOI":"10.1093\/rheumatology\/kew343","article-title":"New targets in psoriatic arthriti","volume":"55","author":"Braun","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"key\n\t\t\t\t2019012308090983800_key312-B10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/1744666X.2017.1257939","article-title":"Treatment of psoriatic arthritis with traditional DMARD's and novel therapies: approaches and recommendations","volume":"13","author":"Maharaj","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"key\n\t\t\t\t2019012308090983800_key312-B11","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1315231","article-title":"Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis","volume":"370","author":"Mease","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019012308090983800_key312-B12","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019012308090983800_key312-B13","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019012308090983800_key312-B14","volume-title":"Stelara (ustekinumab). US prescribing information","year":"2018"},{"key":"key\n\t\t\t\t2019012308090983800_key312-B15","first-page":"518","article-title":"Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid","volume":"24","author":"Partsch","year":"1997","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t2019012308090983800_key312-B16","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/art.38376","article-title":"Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression","volume":"66","author":"Menon","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t2019012308090983800_key312-B17","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/art.38941","article-title":"CD8+ T cell profiles in patients with rheumatoid arthritis and their relationship to disease activity","volume":"67","author":"Carvalheiro","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t2019012308090983800_key312-B18","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.autrev.2016.09.015","article-title":"Are psoriasis and psoriatic arthritis the same disease? The IL-23\/IL-17 axis data","volume":"16","author":"Sakkas","year":"2017","journal-title":"Autoimmun Rev"},{"key":"key\n\t\t\t\t2019012308090983800_key312-B19","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1080\/13543784.2016.1187130","article-title":"A revolutionary therapeutic approach for psoriasis: bispecific biological agents","volume":"25","author":"Torres","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"key":"key\n\t\t\t\t2019012308090983800_key312-B20","doi-asserted-by":"crossref","first-page":"495.1","DOI":"10.1136\/annrheumdis-2014-eular.4676","article-title":"FRI0303 Discovery and characterization of ABT-122, an anti-TNF\/IL-17 DVD-Ig\u2122 molecule as a potential therapeutic candidate for rheumatoid arthritis","volume":"73","author":"Hsieh","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019012308090983800_key312-B21","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1002\/art.40319","article-title":"Safety, tolerability, and pharmacodynamics of ABT-122, a tumor necrosis factor- and interleukin-17-targeted dual variable domain immunoglobulin, in patients with rheumatoid arthritis","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t2019012308090983800_key312-B22","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s40262-017-0580-y","article-title":"Pharmacokinetics of ABT-122, a TNF-alpha- and IL-17A-targeted dual-variable domain immunoglobulin, in healthy subjects and patients with rheumatoid arthritis: results from three phase I trials","volume":"57","author":"Khatri","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"key\n\t\t\t\t2019012308090983800_key312-B23","doi-asserted-by":"crossref","DOI":"10.1002\/art.40579","article-title":"Phase 2 study of ABT-122, a TNF- and IL-17-targeted dual variable domain immunoglobulin, in psoriatic arthritis with inadequate methotrexate response","author":"Mease","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t2019012308090983800_key312-B24","doi-asserted-by":"crossref","DOI":"10.1002\/art.40580","article-title":"ABT-122, a bispecific DVD-immunoglobulin targeting TNF- and IL-17A, in RA with inadequate response to methotrexate: a randomized, double-blind study","author":"Genovese","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t2019012308090983800_key312-B25","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/jcph.1068","article-title":"Population pharmacokinetics of the TNF-alpha and IL-17A dual-variable domain antibody ABT-122 in healthy volunteers and subjects with psoriatic or rheumatoid arthritis: analysis of phase 1 and 2 clinical trials","volume":"58","author":"Khatri","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t2019012308090983800_key312-B26","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0149-2918(03)80164-9","article-title":"Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study","volume":"25","author":"Weisman","year":"2003","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t2019012308090983800_key312-B27","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1038\/psp.2014.41","article-title":"Simultaneous exposure-response modeling of ACR20, ACR50, and ACR70 improvement scores in rheumatoid arthritis patients treated with certolizumab pegol","volume":"3","author":"Lacroix","year":"2014","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"key\n\t\t\t\t2019012308090983800_key312-B28","article-title":"The visual predictive check \u2013 superiority to standard diagnostic (rorschach) plots","volume":"14","author":"Holford","year":"2005","journal-title":"PAGE"},{"key":"key\n\t\t\t\t2019012308090983800_key312-B29","article-title":"A tutorial on visual predictive checks","volume":"17","author":"Karlsson","year":"2008","journal-title":"PAGE"},{"key":"key\n\t\t\t\t2019012308090983800_key312-B30","volume-title":"Ixekizumab. US prescribing information","author":"Eli Lilly and Company","year":"2018"},{"key":"key\n\t\t\t\t2019012308090983800_key312-B31","volume-title":"Secukinumab. US prescribing information","year":"2018"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/58\/2\/352\/27583915\/key312.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T11:32:12Z","timestamp":1720611132000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/58\/2\/352\/5146729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,29]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,10,29]]},"published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/key312","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.734318797.793564286","asserted-by":"object"}]},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,2]]},"published":{"date-parts":[[2018,10,29]]}}}